Opinion|Videos|January 28, 2025
Enhancing Access to BCG-Unresponsive NMIBC Treatments
Author(s)Max Kates, MD
Max Kates, MD, discusses how the ability to deliver newer treatments in local urology clinics rather than specialized centers reduces patient travel burden and improves access to care, while suggesting that increased education about safety profiles and implementation protocols could encourage broader adoption among health care providers.
Advertisement
Episodes in this series
- From an operational standpoint, how important is it that these treatments can be administered by urologists locally, without the need to refer patients to oncology centers? Please discuss overall burden on patients, systemic side effects, and travel to specialized centers
- What strategies would you recommend to encourage more HCPs to adopt newer treatment modalities for BCG-unresponsive NMIBC?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
